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Background: To describe the utilisation of antibiotics in children and adolescents across 5 European countries
based on the same drug utilisation measures and age groups. Special attention was given to age-group-specific
distributions of antibiotic subgroups, since comparison in this regard between countries is lacking so far.
Methods: Outpatient paediatric prescriptions of systemic antibiotics during the years 2005-2008 were analysed
using health care databases from the UK, the Netherlands, Denmark, Italy and Germany. Annual antibiotic
prescription rates per 1,000 person years were estimated for each database and stratified by age (≤4, 5-9, 10-14,
15-18 years). Age-group-specific distributions of antibiotic subgroups were calculated for 2008.
Results: With 957 prescriptions per 1000 person years, the highest annual prescription rate in the year 2008 was
found in the Italian region Emilia Romagna followed by Germany (561), the UK (555), Denmark (481) and the
Netherlands (294). Seasonal peaks during winter months were most pronounced in countries with high utilisation.
Age-group-specific use varied substantially between countries with regard to total prescribing and distributions of
antibiotic subgroups. However, prescription rates were highest among children in the age group ≤4 years in all
countries, predominantly due to high use of broad spectrum penicillins.
Conclusions: Strong increases of antibiotic prescriptions in winter months in high utilising countries most likely
result from frequent antibiotic treatment of mostly viral infections. This and strong variations of overall and
age-group-specific distributions of antibiotic subgroups across countries, suggests that antibiotics are
inappropriately used to a large extent.
Keywords: Drug utilisation study, Antibiotic resistance, Paediatric, Prescription rate, Cephalosporins, Macrolides,
Penicillins, Electronic healthcare databaseBackground
Antibiotics are among the most widely prescribed medi-
cations in Europe [1]. Resistance to common antibiotic
agents has grown among a majority of bacterial patho-
gens and is widely acknowledged to be an increasing
threat to global public health [2,3]. Population exposure
to antibiotics is recognised as an important cause for the
emergence of resistant bacterial strains [4-6]. Due to a* Correspondence: garbe@bips.uni-bremen.de
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unless otherwise stated.high burden of respiratory infections in paediatric popu-
lations, antibiotic prescribing is particularly common in
the treatment of childhood diseases. However, frequent
childhood respiratory conditions such as sore throat,
acute otitis media, acute cough, sinusitis, common cold,
and acute bronchitis are predominantly caused by vi-
ruses and mostly do not benefit from antibiotic therapy
[7-10]. Thus, high prescribing of antibiotic agents to the
paediatric population is a recognised indicator for in-
appropriate prescribing patterns in primary care [11].
Several studies have been published in the last decade
either assessing antibiotic use in paediatric populationsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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parisons of paediatric antibiotic use between up to three
countries [16,17]. Findings showed wide variations across
Europe in the prescribing of systemic antibiotics to chil-
dren and adolescents [12]. Comparability of these studies
was, however, limited due to differences in drug utilisa-
tion measures, inclusion criteria of the study popula-
tions, age group categorizations and classifications of
antibiotic subgroups [11-18]. In addition, comparison of
the age-group-specific distributions of antibiotic sub-
groups between countries is lacking so far.
The aim of the present study was to compare out-
patient prescribing of systemic antibiotics to children
and adolescents in the age group 0-18 years between
Denmark, Italy, Germany, the Netherlands and the UK
for the years 2005-2008, based on a standardised proto-
col for data extraction and analysis for each database in
these countries. Special attention was paid to differences
of age-group-specific use of different antibiotic sub-
groups across countries. Seasonal variations of prescrib-
ing rates were described to assess impact of antibiotic
treatment of mostly viral respiratory infections during
winter months on total use.
Methods
Data sources
Data were retrieved from one general practice database
(The Health Improvement Network (THIN), UK), one out-
patient pharmacy dispensing database (PHARMO, the
Netherlands) and three claims databases (Aarhus University
Hospital Database, Denmark; German Pharmacoepide-
miological Research Database (GePaRD), Germany; Emilia
Romagna regional database, Italy). These electronic health-
care databases cover a total source population of about
23 million persons. All databases are in compliance with
European Union guidelines on the usage of medical data
for research. The study was given approval by regulatory
agencies or by scientific and ethical advisory boards of
the databases where applicable. All five databases com-
prise medical information of a defined population. De-
tailed descriptions of these databases including specifics
regarding approvals for use of data for this study are
enclosed as Additional file 1.
Study design and statistical analysis
The study was conducted in an open (dynamic) cohort de-
sign. The study period was from January 2005 to Decem-
ber 2008, since for some databases no more recent data
was available at the time of the analysis. The observational
period of the Italian Emilia Romagna Database was re-
stricted to the years 2007 and 2008, since data of the years
2005 and 2006 were not available. Cohort start was
defined as January 1st 2005 or – if later - the first date a
person entered into the respective database. Cohort exitwas defined as exit of the person from the database, 18th
birthday, death, the first interruption of follow-up in the
database or December 31st 2008, whichever came first.
Over the follow-up period, members of the study popu-
lation could contribute to more than one age category.
Children and adolescents up to the age of 18 years were
included and divided into the age groups ≤4, 5-9, 10-14,
and 15-18 years. This age group classification was
chosen, since it was commonly used in other studies of
antibiotic utilisation in the paediatric setting and hence
allows comparison of age-group-specific use across
studies [11,15,19,20].
Utilisation of systemic antibiotics (Anatomical Thera-
peutic Chemical (ATC) code: J01) was measured as the
annual prescription rate, i.e. the number of prescriptions
divided by 1,000 person years. Person years rather than
individuals were used as denominator, given that not all
children could be followed for an entire year. Prescrip-
tion rates were chosen as a main outcome measure in-
stead of Defined Daily Doses (DDDs) per person time,
since dosing of antibiotics depends on a patient’s age
and body weight. Prescription rates are therefore more
appropriate to describe antibiotic use among children
and conduct comparison between children in different
age groups than DDDs per person time [12]. Seasonal
trends were analysed by monthly prescription rates per
1,000 person years. To express utilisation on the level of
chemical substances, the annual prescription rate per
1,000 person years, was estimated for single agents for
the year 2008 as this was the year to which all databases
contributed.
Outpatient prescriptions of systemic antibiotics were
divided into the following subgroups (ATC codes in
brackets): Tetracyclines (J01AA), broad spectrum penicil-
lins (J01CA, J01CR), narrow spectrum penicillins (J01CE,
J01CF), second generation cephalosporins (J01DC), third
generation cephalosporins (J01DD), sulphonamides/tri-
methoprim (J01EB, J01EE, and J01EA), macrolides (J01FA)
and nitrofuran derivatives (J01XE). Less frequent antibiotics
were pooled in the subgroup ‘others’.
To describe differences in the distribution of antibiotic
subgroups between countries, age-group-specific propor-
tions of antibiotic subgroups were calculated for each
database in the year 2008 based on the respective total
number of systemic antibiotic prescriptions per age group.
Local data extraction was conducted by using standar-
dised purpose-built Jerboa® software, which was previously
developed by the Erasmus University Medical Center and
tested against different scripts [21]. Measures of antibiotic
utilisation as much as the corresponding numerators and
denominators for each database population were calcu-
lated locally on different levels of the ATC Classification
System, stratified by age in years, sex, calendar months
and calendar year. These analyses followed a common
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remote research environment (RRE) at Erasmus University
in Rotterdam, the Netherlands, which could be accessed
via a secured password to conduct further statistical
analyses. These further analyses were conducted using
SAS® 9.2.
Results
The average annual total population comprised 334,991
children from Denmark, 773,492 children from the Italian
region Emilia Romagna, 1,340,163 children from Germany,
622,450 children from the Netherlands and 798,253 children
from the UK.
With 957.2 prescriptions per 1,000 person years, the
highest annual prescription rate in the year 2008 was
found in Emilia Romagna (Italy) followed by Germany
(560.8), UK (555.2), Denmark (481.0) and the Netherlands
(294.2). This ranking did not change over the entire obser-
vational period, with the restriction, that data from Italy
was only available for the years 2007 and 2008 (Table 1).
In all five countries and all years, the highest prescrip-
tion rates were found in the age group ≤4 years and the
lowest rates were observed in the age group 10-14 years
(Table 1).
Prescription rates in children and adolescents in the
Netherlands and the UK fluctuated slightly between theTable 1 Annual prescription rates per 1,000 person years of s
(children and adolescents ≤18 years)
Aarhus (DK) Emilia Romagnaa (IT
2005 ≤4 800.0 .
5-9 356.9 .
10-14 264.0 .
15-18 451.9 .
0-18 467.7 .
2006 ≤4 869.5 .
5-9 384.7 .
10-14 285.1 .
15-18 497.3 .
0-18 503.8 .
2007 ≤4 977.1 1486.8
5-9 386.9 1055.1
10-14 285.0 661.0
15-18 528.1 682.7
0-18 531.1 1043.8
2008 ≤4 981.8 1392.8
5-9 325.1 982.8
10-14 234.7 579.3
15-18 504.4 610.2
0-18 481.0 957.1
aObservational period of Emilia Romagna Database was available only for the yearsyears 2005 and 2008, overall and in different age groups
(Table 1). Similarly, the number of prescriptions per
1,000 person years in Danish children changed margin-
ally throughout the course of the study. Nevertheless, an
increase by 22.7% could be observed in the age group ≤4
years between 2005 and 2008 (Table 1). In Germany, a
progressive decline of the annual prescription rates could
be observed over all four age groups during the study
period (Table 1).
Monthly prescription rates were lowest in July and
August and rose continuously until reaching their peak
between December and March of the following year.
Seasonal increases in the winter months were most pro-
nounced in Italy followed by Germany (Figure 1).
In all countries except Denmark, broad-spectrum pen-
icillins formed the largest subgroup of prescribed sys-
temic antibiotics, with proportions varying between
23.8% in Germany and 57.4% in Italy (Table 2). Propor-
tions of broad spectrum penicillins were highest in the
age group ≤4 years and decreased gradually with age in
all five countries. Narrow-spectrum penicillins were most
widely used in Denmark (51.7%) and covered different
proportions in the four other countries, from 0.1% (Italy)
to 23.5% (UK) (Table 2).
Cephalosporins were hardly prescribed to Danish and
Dutch children, whereas second and third generationystemic antibiotics per age group in the years 2005-2008
) GePaRD (DE) PHARMO (NL) THIN (UK)
984.7 519.4 891.5
683.0 275.0 486.4
441.1 147.2 385.4
601.2 250.7 582.3
664.6 296.9 575.2
949.7 543.9 882.8
656.9 288.1 478.0
405.9 160.2 386.2
565.7 267.8 581.0
628.9 312.2 572.5
931.0 543.6 918.2
604.6 259.4 485.2
378.8 151.6 391.1
556.9 277.9 597.7
600.8 303.4 590.8
853.5 523.2 843.1
560.4 256.3 450.9
347.1 144.1 367.8
561.5 274.5 581.1
560.8 294.2 555.2
2007 and 2008.
Figure 1 Trends in monthly antibiotic prescription rates per 1,000 person years and country during the observed years (2005-2008)a
in children and adolescents (≤18 years of age). aObservational period of Emilia Romagna Database was available only for the years 2007
and 2008.
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in Germany and Italy, respectively. Relative use of sec-
ond and third generation cephalosporins was highest in
the age group ≤4 years and gradually decreased with age
(Table 2).
Use of macrolides increased with age and accounted for
20.7% of total use in Italy, 20.3% in Germany, 16.0% in the
Netherlands, 12.5% in the UK and 13.5% in Denmark.
Proportions of macrolide use increased with age (Table 2).
Overall, tetracyclines covered varying proportions, from
0.4% in Denmark to 7.8% in the UK. In line with age re-
strictions, relevant relative use of tetracyclines was only
found above ten years of age in all five countries (Table 2).
Amoxicillin and clarithromycin were among the 12
agents with the highest annual prescription rates in all da-
tabases (Table 3). Amoxicillin was either the most or
among the three most commonly prescribed agents. Only
in Italy, Amoxicillin plus enzyme inhibitor showed the
highest prescription rate. Phenoxymethylpenicillin (e.g.
penicillin V) was most prescribed in Denmark and was
also frequently prescribed in Germany and the UK. In
contrast, this agent was not prescribed to Italian children
and its use in the Netherlands was negligible (Table 3).
Discussion
Our study provides comprehensive information on the
utilisation of systemic antibiotics among children and ado-
lescents in the age group ≤18 years in Denmark, Italy,
Germany, the Netherlands and the UK during the years
2005 to 2008. Our findings illustrate striking variations of
total systemic antibiotic use in paediatric outpatient carebetween these countries. Substantial differences of out-
patient antibiotic use among children across Europe have
been described before, but these previous studies only
provided comparable data of drug use for up to three
countries and suffered from different definitions of drug
utilisation measures. Furthermore, comprehensive data
about age-group-specific distributions of antibiotic sub-
groups was lacking for most countries of this study and
a comparison has not been conducted so far. In 2001, the
European Surveillance of Antimicrobial Consumption
Project was established to gather reliable and comparable
information on the utilisation of antibiotics in Europe,
however, without distinguishing between adults and
children [1]. The current study captured outpatient sys-
temic paediatric antibiotic use of five countries in different
European regions ensuring high inter-country comparabil-
ity, due to consistent definition of drug utilisation mea-
sures, age groups and classification of antibiotic subgroups.
Overall, the annual antibiotic prescription rates in the
Italian region Emilia Romagna were more than three
times higher than those in the Netherlands, the country
with the lowest prescription rates, and still substantially
higher than those in Germany, the country with the sec-
ond highest use. When compared to other studies, mag-
nitude of paediatric antibiotic use in Italy exceeded use
reported for Canada (608 prescriptions per 1000 chil-
dren <15 years of age in 2003) [19] and Sweden (764
prescriptions per 1000 children 0-6 years of age in 2002)
[15] as well, but appears to be comparable to the U.S.
(910 prescriptions per 1000 person years in children <18
years of age in 2001) [22].
Table 2 Distribution of systemic antibiotic subgroupsa by age group in 2008 (children and adolescents ≤18 years)
Aarhus (DK) Emilia Romagna (IT) GePaRD (DE) PHARMO (NL) THIN (UK)
≤ 4 5-9 10-14 15-18 0-18 ≤ 4 5-9 10-14 15-18 0-18 ≤ 4 5-9 10-14 15-18 0-18 ≤ 4 5-9 10-14 15-18 0-18 ≤ 4 5-9 10-14 15-18 0-18
Tetracyclines - - 0.3 1.7 0.4 <0.1 <0.1 1.1 4.1 0.6 <0.1 0.1 3.8 11.7 3.3 <0.1 0.1 9.6 24.2 6.7 <0.1 <0.1 8.6 26.3 7.8
Broad spectrum penicillins 47.8 24.2 12.7 14.8 31.0 62.4 57.5 51.3 44.0 57.4 28.4 23.5 23.3 17.5 23.8 73.3 60.3 43.0 21.8 54.9 62.0 47.3 34.7 20.8 44.2
Narrow spectrum penicillins 42.6 63.8 69.4 48.5 51.7 <0.1 0.1 0.2 0.2 0.1 11.7 19.8 15.4 12.7 14.8 4.9 9.7 13.7 12.7 8.9 16.0 28.1 31.8 25.1 23.5
Second generation cephalosporins <0.1 <0.1 <0.1 <0.1 <0.1 5.1 4.7 3.0 2.0 4.3 27.5 21.1 15.6 8.7 19.4 0.1 0.3 0.1 0.1 0.2 1.2 1.1 0.8 0.4 0.9
Third generation cephalosporins - - - <0.1 <0.1 14.7 14.8 13.9 10.6 14.1 8.8 5.9 5.2 3.8 6.3 <0.1 <0.1 0.1 0.2 0.1 0.1 0.1 0.1 <0.1 0.1
Sulfonamides/trimethoprim 0.9 2.8 3.5 9.5 3.6 0.4 0.5 0.7 1.0 0.5 3.8 5.4 5.5 7.8 5.4 5.3 7.1 6.3 6.5 6.1 4.9 6.4 5.2 7.7 5.9
Macrolides 8.3 7.6 13.0 24.7 12.5 16.7 21.0 27.2 28.9 20.7 16.7 18.8 24.9 23.5 20.3 15.2 17.4 18.7 14.2 16.0 12.2 11.7 13.7 12.6 12.5
Nitrofuran derivatives 0.1 1.4 0.8 0.7 0.6 <0.1 <0.1 <0.1 <0.1 <0.1 0.2 0.6 0.4 0.4 0.4 0.7 4.3 6.9 16.3 5.8 0.2 0.5 0.4 0.8 0.4
Others 0.2 0.2 0.3 0.3 0.2 0.6 1.4 2.8 9.1 2.1 2.8 4.7 5.9 13.9 6.3 0.5 0.9 1.8 3.9 1.4 3.4 4.8 4.7 6.3 4.6
aIn column percentages, based on total number of systemic antibiotic prescriptions per age group.
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Table 3 Annual prescription rates per 1,000 person years of single antibiotic agents and combinations in 2008
(children and adolescents ≤18 years)
Antibiotic agenta Aarhus (DK) Emilia Romagna (IT) GePaRD (DE) PHARMO (NL) THIN (UK)
Tetracyclines
Doxycycline 0.2 1.2 10.6 11.9 6.3
Lymecycline 0.6 1.5 . . 16.4
Oxytetracycline <0.1 . . . 13.9
Minocycline . 3.4 6.3 6.9 6.1
Penicillines
Amoxicillin 121.5 230.8 120.7 124.1 221.0
Pivmecillinam 17.6 . . . <0.1
Phenoxymethylpenicillin 219.1 . 70.5 0.3 71.9
Pheneticillin - - - 15.9 -
Dicloxacillin 29.4 . <0.1 . .
Flucloxacillin 0.1 <0.1 0.4 9.7 58.2
Amoxicillin plus enzyme inhibitor 7.3 318.0 11.0 37.6 23.3
Cephalosporines
Cefalexin <0.1 0.7 1.2 <0.1 16.6
Cefadroxil . 0.4 12.5 . 0.6
Cefuroxime 0.1 8.8 25.2 0.3 0.2
Cefaclor . 27.9 81.2 0.2 5.0
Ceftriaxone <0.1 9.8 0.2 0.1 <0.1
Cefixime . 58.6 16.1 . 0.4
Cefpodoxime . 43.5 16.0 . <0.1
Ceftibuten . 22.6 2.9 <0.1 .
Sulfonamides and Trimethoprim
Trimethoprim 2.9 . 4.1 5.5 32.0
Sulfamethizole 14.2 . . . .
Sulfamethoxazole and trimethoprim . 5.1 26.2 12.4 0.8
Macrolides
Erythromycin 27.0 1.6 36.8 4.0 56.8
Roxithromycin 7.1 3.2 16.1 0.1 .
Clarithromycin 5.4 96.7 26.5 16.9 8.5
Azithromycin 20.8 92.1 34.3 25.8 4.1
Nitrofuran derivatives
Nitrofurantoin 2.8 <0.1 2.1 17.0 2.3
Other antibacterials
Fosfomycin . 9.2 0.6 0.2 .
Others 5.0 22.0 38.9 5.3 10.5
aThe 12 most prescribed agents per database in 2008 were selected. Remaining agents were labelled as ‘others’.
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ting compared to the other countries in our study might
be related to differences with regard to historical back-
grounds, cultural and social factors, awareness about anti-
biotic resistance in the community and among healthcare
providers [23] as well as the ability of physicians toadequately diagnose common infectious diseases [16]. So
far, reasons for strong variations of antibiotic use across
European countries have not yet been fully investigated.
Nevertheless, previous studies suggest that awareness
about antibiotic resistance [24] and inadequacy of antibi-
otics to treat viral infections [25] is poor among Italian
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physicians is a major determinant of antibiotic prescribing
to children [26].
In contrast, several previous studies showed antibiotic
utilisation in the Netherlands to be lowest in Europe,
overall and in the paediatric setting [6,13]. The Netherlands
are a country with a strict prescribing policy for antiin-
fectives, and there are intensive efforts into promoting
guideline-appropriate prescribing habits to combat anti-
biotic resistance [27].
Although antibiotic use was by far the highest among
Italian children and adolescents, antibiotic prescription
rates in Denmark, Germany and UK still exceeded those in
the Netherlands to a great extent. These observed strong
variations of total paediatric antibiotic use among the
countries of study are unlikely to reflect an actual thera-
peutic need which would have to be based on marked dif-
ferences in the burden of infectious diseases between these
countries. This assumption is also supported by the ob-
served pronounced increases of prescription rates during
winter months which were expectedly highest in Italy, and
smallest in the Netherlands. Increases of antibiotic use are
most likely related to seasonal rise of predominantly viral
respiratory infections and hence should be limited [1].
Since our findings could not provide information be-
yond the 4-year study period, we compared our prescrip-
tion rates with those of other studies which included other
study years or longer time periods. In this respect, our
data for the years 2005-2008 in the Netherlands agreed
well with the findings by de Jong et al. who reported a
variation of the total annual number of antibiotic prescrip-
tions between 282 and 307 per 1,000 Dutch children in
the years 1999-2005 [13]. This suggests an overall stable
total antibiotic use among Dutch children for almost ten
years. Gagliotti et al. observed annual prescription rates
per 1,000 person years among children 0-14 years of age
from Emilia Romagna, varying between 1,158 and 1,358
during 2000-2002 [13]. This is in line with our findings in
children below 15 years of age of 1,123 (2007) and 1,034
prescriptions per 1,000 person years (2008), indicating
marginal changes over time of total paediatric use in
Emilia Romagna. Prescription rates among British chil-
dren did not show any apparent trend towards lower or
higher prescribing in our study over the study years. Grad-
ual annual increases of prescription rates between 2000
and 2007 were reported in the UK based on data from the
General Practice Research Database (GPRD) [11]. How-
ever, differences to our findings for the years 2005 to 2007
were small and might have resulted from variations in the
regional distribution of general practices contributing data
to THIN and/or the GPRD. We observed a steady de-
crease in prescription rates in Germany during 2005-2008.
Another German study also based on GePaRD data found
slightly higher prescription rates among German childrenwithout an obvious downward trend for the years 2004-
2006 [18]. This former study, however, included data from
four rather than three health insurances, resulting in a
study population of about twice as many children as in
this study which may explain the difference.
We also detected remarkable differences in the choice
of antibiotic subgroups between the countries of our
study. Narrow spectrum penicillins formed the majority of
systemic antibiotics in Denmark, whereas prescriptions
of broad spectrum penicillins were most frequent in the
four other countries. In line with that, the highest agent-
specific prescription rates were reported for phenoxy-
methylpenicillin in Denmark, amoxicillin in Germany, the
Netherlands and the UK and amoxicillin plus enzyme in-
hibitor in Italy. Relatively high use of narrow spectrum
penicillins in Denmark in comparison to other European
countries has also been reported previously [6]. However,
it is noteworthy that even though proportions for narrow
spectrum penicillins were highest in Denmark, broad
spectrum penicillins formed the antibiotic subgroup most
frequently prescribed to children in the age group ≤4 years
in all 5 countries. This might be due to frequent use of
amoxicillin or amoxicillin and enzyme inhibitor in the
treatment of acute otitis media, which shows the highest
incidence in the first two years of life [28].
Macrolides were commonly prescribed in all five coun-
tries with the highest use in the age groups 10-14 and 15-
18 years. Relative proportions of macrolide use were lowest
in Denmark. This finding is in agreement with a Danish
practice guideline which recommends restricting the use of
macrolides to patients with penicillin allergies in the treat-
ment of common childhood infections [21]. Several studies
from the U.S. and Europe show a strong association of
high macrolide use and the emergence of resistant strains
of pneumococci and other common pathogens [23-25].
Hence high prescription rates of macrolides are question-
able and likely to unnecessarily increase selective pressure
on bacterial pathogens. In particular high use of clarithro-
mycin and azithromycin in the Emilia Romagna region
appears unjustified, since international guidelines do not
recommended these agents as first-line treatment of com-
mon childhood infections [29-32]. Furthermore, longer
plasma half-life of azithromycin and clarithromycin in con-
trast to erythromycin might even accelerate the emergence
of antibiotic resistance [33,34].
Our findings regarding paediatric cephalosporin use
are in line with previous studies which reported strong
variations of cephalosporin prescribing across Europe,
with the lowest prescription rates in the Netherlands and
Denmark [13,18-20,35]. Overall, the prescription rate of
cefaclor (a second generation cephalosporin) in German
children was the second highest after amoxicillin, and
use of second generation cephalosporins was particu-
larly common in very young children. Only in Italy, the
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one was prescribed frequently. Considerably higher pre-
scribing of parenteral antibiotics in Italian outpatient care
in contrast to Northern European countries has been re-
ported previously [36]. The high relative use of cephalos-
prines in Germany and Italy as observed here, suggests
frequent prescribing of these antibiotics as a first–line
treatment of common paediatric respiratory infections.
This is in conflict with international practice guidelines
[29,30] recommending that cephalosporins should be pre-
served for second-line treatment in cases such as treat-
ment failure of first-line agents, non-type 1 allergy to
penicillins or unusually severe symptoms.
Strengths and limitations
Our study overcomes limitations of previous studies and
facilitates the comparison of paediatric antibiotic prescrip-
tions in five countries based on a common protocol using
the same drug utilisation measures. It provides insight into
the age-group-specific distributions of antibiotic subgroups
in the paediatric setting of the participating countries. As-
certainment of antibiotics prescribed in the outpatient set-
ting was complete in all databases except Denmark, where
some antibiotics as e.g. cephalosporins are reimbursable
only in particular circumstances and might therefore have
been underascertained. Nevertheless, given that the Danish
National Health System reimburses antibiotics for the en-
tire spectrum of childhood indications, [37] the proportion
of antibiotics which could not be captured due to private
prescribing appears to be small. Besides this, differences of
antibiotic use across countries reflect differences in pre-
scribing behaviour of outpatient providers and not in the
type of data.
Our study has some limitations, which have to be taken
into consideration. First, for this study only data for the
years 2007 and 2008 was available from the Northern
Italian region Emilia Romagna. Hence, insight into the
development of antibiotic prescribing over time is limited.
However, our findings are in good agreement with
Gagliotti et al. [14] In addition, extrapolation from our
findings to Italy in general is not straight forward, given
considerable regional differences of prescribing patterns in
Italy. Nonetheless, previous studies about marked hetero-
geneity of antibiotic use across Italy with up to 19% higher
paediatric prevalence rates of antibiotic exposure in south-
ern regions compared to Emilia Romagna [35] indicate,
that overall paediatric antibiotic use in the Italian out-
patient setting during the years of our study might have
been even higher than suggested by our findings.
Since all five databases only provide information on drugs
prescribed in the outpatient setting, antibiotics adminis-
tered to inpatients to treat severe childhood infections
could not be studied. Given that indications underlying the
issued prescriptions were not available in all databases, theappropriateness of single treatment courses could not be
assessed. Additionally, compliance with the antibiotic pre-
scription remains unknown.
Conclusions
Comparison of paediatric antibiotic consumption between
different European countries revealed a wide variability of
antibiotic prescribing patterns. Strong variations of overall
and age-group-specific distributions of antibiotic subgroups
across countries, suggests that antibiotics are inappropri-
ately used to a large extent. Considerably higher prescrip-
tion rates along with higher seasonal increases, particularly
in Italy, in contrast to the Netherlands suggest frequent
utilisation of antibiotics in the treatment of mostly viral re-
spiratory infections. This study showed the benefit of using
a common methodological approach to provide compar-
able and detailed data on paediatric antibiotic prescribing
across Europe. Study results allow health care practitioners
and policy makers to audit country and age-group-specific
patterns of paediatric antibiotic use with regard to both
total level of prescribing and the distribution of antibiotic
subgroups/substances.
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